|
AstraZeneca PLC on Tuesday announced that its new drug application under US Food & Drug Administration priority review for its selective inhibitor baxdrostat for certain patients has been accepted. The Cambridge, England-based pharmaceutical company said the new drug application aims at treating adult patients with hard-to-control hypertension. Further, it could be used as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pressure, the firm added. AstraZeneca noted that ‘if approved, baxdrostat could be the first aldosterone synthase inhibitor to receive regulatory authorisation.’ Sharron Barr, executive vice president at AstraZeneca’s BioPharmaceuticals research & development, said: ‘This priority review demonstrates our commitment to advancing baxdrostat as a potential first- and best-in-class aldosterone synthase inhibitor for the millions of people living with hard-to-control hypertension as quickly as possible. The substantial reduction in systolic blood pressure seen in the BaxHTN trial underscores baxdrostat’s novel mechanism of action and its potential to bring innovation to a disease area that has seen limited progress in over two decades.’ Baxdrostat is designed to lower blood pressure by inhibiting the production of aldosterone, a key hormone that raises blood pressure and increases the risk of heart and kidney problems. AstraZeneca shares were 0.3% lower at 13,792.00 pence each on Tuesday morning in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
